Search Result

Results for "

multidrug-resistant strains

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Antibiotic (6) Apoptosis (2) Bacterial (33) Bcl-2 Family (1) Caspase (1) CCR (1) Cytochrome P450 (1) Dihydrofolate reductase (DHFR) (2) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (3) Endogenous Metabolite (1) Epigenetic Reader Domain (1) HDAC (2) HIV (2) HIV Protease (1) HSV (1) Microtubule/Tubulin (1) MMP (1) p38 MAPK (1) Parasite (12) Potassium Channel (1) Survivin (1) Virus Protease (1)
By Research Areas:	Cancer (3) Infection (46)

By Targets:

ADC Payload (1)

Antibiotic (6)

Apoptosis (2)

Bacterial (33)

Bcl-2 Family (1)

Caspase (1)

CCR (1)

Cytochrome P450 (1)

Dihydrofolate reductase (DHFR) (2)

Dihydroorotate Dehydrogenase (1)

DNA/RNA Synthesis (3)

Endogenous Metabolite (1)

Epigenetic Reader Domain (1)

HDAC (2)

HIV (2)

HIV Protease (1)

HSV (1)

Microtubule/Tubulin (1)

MMP (1)

p38 MAPK (1)

Parasite (12)

Potassium Channel (1)

Survivin (1)

Virus Protease (1)

By Research Areas:

Cancer (3)

Infection (46)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128914

Tubulysin	ADC Payload Microtubule/Tubulin Apoptosis	Cancer
Tubulysin is a microtubule destabilizer that binds to the β-tubulin peptide site adjacent to the vinca alkaloid binding site and inhibits tubulin polymerization. Tubulysin induces apoptosis and exhibits antiproliferative activity against a variety of human cancer cells, including multidrug-resistant strains. Tubulysin can be conjugated to antibodies via a disulfide-containing quaternary ammonium linker for ADC synthesis . Tubulysin is applicable to tumor-related research .

HY-15975

GNF179	Parasite	Infection
GNF179 is an optimized 8,8-dimethyl imidazolopiperazine analog that exhibits antimalarial potency (IC₅₀ of 4.8 nM against the multidrug resistant strain W2). GNF179 is orally active .

HY-Y0191

α-Pyridone 2-Pyridone	Endogenous Metabolite Bacterial	Infection
α-Pyridone (2-Pyridone) is an antibacterial agent that plays an important role in the field of biochemical research. α-Pyridone can serve as a scaffold compound to synthesize a variety of active compounds .

HY-135813

LtaS-IN-1 1 Publications Verification	Bacterial	Infection
LtaS-IN-1 (compound 1771) is a potent small-molecule inhibitor of Lipoteichoic acid (LTA) synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 alone inhibits Enterococcus.spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 combination with antibiotics abolishs multidrug-resistant E. faecium growth almost completely .

HY-P10233A

SAAP 148 TFA	Bacterial	Infection
SAAP 148 TFA is a synthetic antimicrobial peptide (bacteria) that interacts with and disrupts the lipid bilayer of bacterial cytoplasmic membranes, thereby inducing changes in membrane permeability and bacterial death. SAAP 148 TFA kills drug-resistant, multidrug-resistant and persister bacterial strains, inhibits biofilm formation, eliminates established biofilms, and blocks bacterial colonization on implant surfaces. SAAP 148 TFA retains its activity after modification or immobilization, exhibits variable cytotoxicity in different human cell models, and shows reduced efficacy in protein-rich environments. SAAP 148 TFA can be used in infection-related research .

HY-N5109

Cheilanthifoline	Parasite	Infection
Cheilanthifoline, an alkaloid, is isolated from Corydalis calliantha. Cheilanthifoline exhibits antiplasmodial activities against Plasmodium falciparum, with IC₅₀s of 0.90 μg/mL and 1.22 μg/mL for wild type (TM4) and multidrug resistant (K1) strains, respectively .

HY-135578

Artelinic acid	Parasite	Infection
Artelinic acid, a derivative of Artemisinin, is an antimalarial agent for the treatment of multidrug resistant strains of Plasmodium falciparum. Artelinic acid can be administered by various routes of administration, including intravenous, intramuscular and oral routes .

HY-P3328A

MDP1 acetate	Bacterial	Infection
MDP1 acetate, a Melittin-derived peptide, alters the integrity of both Gram-positive and Gram-negative bacterial membranes and kills the bacteria via membrane damages. MDP1 acetate has a high-antibacterial activity against multidrug resistant (MDR) and reference strains of S. aureus, E. coli, and P. aeruginosa .

HY-P10233

SAAP 148	Bacterial	Infection
SAAP 148 is a synthetic antimicrobial peptide (bacteria) that interacts with and disrupts the lipid bilayer of bacterial cytoplasmic membranes, thereby inducing changes in membrane permeability and bacterial death. SAAP 148 kills drug-resistant, multidrug-resistant and persister bacterial strains, inhibits biofilm formation, eliminates established biofilms, and blocks bacterial colonization on implant surfaces. SAAP 148 retains its activity after modification or immobilization, exhibits variable cytotoxicity in different human cell models, and shows reduced efficacy in protein-rich environments. SAAP 148 can be used in infection-related research .

HY-170219

RMM23	Parasite Epigenetic Reader Domain	Infection
RMM23 is an inhibitor targeting PfBDP1 with a K_d value of 1.24 μM. RMM23 against the wild-type strains 3D7 and NF54, and the multidrug-resistant K1 strain in vitro blood stage, with EC₅₀ values of 18 μM, 14 μM, 20 μM, respectively .

HY-146158

Fudapirine WX-081	Bacterial Potassium Channel Antibiotic	Infection
Fudapirine, an anti-tuberculosis agent, displays excellent anti-mycobacterial activity against M. tuberculosis H37Rv and low cytotoxicity. Fudapirine exhibits potent activity with MIC50s of 0.083 and 0.11 μg/mL for agent susceptible tuberculosis (DS-TB) and multidrug resistant tuberculosis (MDR-TB) strains. Fudapirine also inhibits hERG channel with the IC50 of 1.89 μM.

HY-179415

DHFR-IN-24	Dihydrofolate reductase (DHFR) Bacterial	Infection
DHFR-IN-24, a benzothiazole derivative, is a dihydrofolate reductase (DHFR) inhibitor. DHFR-IN-24 has intrinsic antibacterial activity against both Gram-positive and Gram-negative strains. DHFR-IN-24 synergistically combines DHFR inhibition with photodynamic therapy (PDT) for enhanced antibacterial activity against multidrug-resistant pathogens .

HY-178436

Antituberculosis agent-16	Bacterial	Infection
Antituberculosis agent-16 is an orally active antituberculosis agent. Antituberculosis agent-16 exhibits stable antituberculosis activity with a MIC of 0.48 μg/mL against Mycobacterium tuberculosis H37Rv sensitive strain and 0.49 μg/mL against multidrug-resistant strain 14862. Antituberculosis agent-16 shows high Caco-2 permeability. Antituberculosis agent-16 can be used for the research of infection .

HY-126640

Phomoxanthone A	Parasite	Infection Cancer
Phomoxanthone A is a xanthone dimer, which can be isolated from Phomopsis. Phomoxanthone A exhibits antimalarial and antitubercular activities against Plasmodium falciparum (K1, multidrug-resistant strain, IC₅₀ is 0.11 µg/mL) and Mycobacterium tuberculosis (H37Ra strain, MIC is 0.50 µg/mL). Phomoxanthone A exhibits cytotoxicity in cells KB, BC-1 and Vero, IC₅₀ is 0.99, 0.51 and 1.4 µg/mL, respectively .

HY-121348

Ficellomycin U-47929	Antibiotic Bacterial DNA/RNA Synthesis	Infection
Ficellomycin is a nitrogen-containing bicyclic antibiotic with strong activity against Gram-positive bacteria, including multidrug-resistant strains of Staphylococcus aureus. Ficellomycin works by inducing the formation of defective 34S DNA fragments, which interfere with the semi-conservative DNA replication process. These fragments lack the ability to integrate into larger DNA segments and eventually form a complete bacterial chromosome. Ficellomycin can be used in research for various bacterial diseases .

HY-103250

PF-945863	Antibiotic	Infection
PF-945863 is an orally active macrolide antibiotic that can be used for the research of multidrug resistant respiratory tract bacterial strains .

HY-116736

BRD7539	Dihydroorotate Dehydrogenase Parasite	Infection
BRD7539 is a PfDHODH inhibitor (IC₅₀ = 0.033 μM). BRD7539 has potent activity against both multidrug-resistant asexual blood-stage (P. falciparum, Dd2 strain, EC₅₀ = 0.010 μM) and liver-stage (P. berghei, EC₅₀ = 0.015 μM) parasites .

HY-N8388

Collinin	Bacterial	Infection
Collinin is a anti-tubercular agent, it can be isolated from leaves of Z. schinifolium. Collinin has an excellent anti-tuberculosis effect against multidrug-resistant (MDR), extensively drug-resistant (XDR) strains .

HY-10845

CGI-17341	Bacterial	Others
CGI-17341 is a 5-nitroimidazole antibacterial agent that has the activity of inhibiting sensitive and multidrug-resistant strains of Mycobacterium tuberculosis in vitro and prolonging the survival time of mice infected with Mycobacterium tuberculosis in vivo in a dose-dependent manner.

HY-N15374

Hypercalin B	Bacterial	Infection
Hypercalin B is an antibacterial agent that can be isolated from the hexane and chloroform extracts of the plant Hypericum acmosepalum. Hypercalin B exhibits inhibitory activity against multidrug-resistant strains of Staphylococcus aureus, with a MIC range of 0.5-128 mg/L .

HY-163984

Antibacterial agent 240	Bacterial	Infection
Antibacterial agent 240 (compound 62-7c) is an antibacterial agent that can target multidrug-resistant (MDR) MRSA strains. Antibacterial agent 240 showed high biosafety and potent anti-infection activity in mouse pneumonia and mouse wound models of MRSA infection .

HY-162261

Antibacterial agent 186	Bacterial	Infection
Antibacterial agent 186 (compound 25) is a potent antibacterial agent. Antibacterial agent 186 shows antibiofilm-forming properties against clinical Staphylococcus epidermidis strains and demonstrates the capacity to eliminate existing biofilm layers. Antibacterial agent 186 has the potential for the research of multidrug-resistant Staphylococcus epidermidis .

HY-144297

HDAC1-IN-3	HDAC Parasite	Infection
HDAC1-IN-3 is a potent Pf HDAC1 inhibitor. HDAC1-IN-3 shows antimalarial activity in wild-type and multidrug-resistant parasite strains. HDAC1-IN-3 shows a significant in vivo killing effect against all life cycles of parasites .

HY-N11879

6-C-Methylquercetin-3,4'-dimethyl ether	Bacterial Antibiotic	Others
6-C-Methylquercetin-3,4'-dimethyl etheris a flavonol derivative isolated from the leaves of Bauhinia thonningii Schum. 6-C-Methylquercetin-3,4'-dimethyl ether has antibacterial activity against Gram-negative multidrug-resistant bacteria and against methicillin-resistant Staphylococcus aureus (MRSA) strains .

HY-175262

Mtb-IN-12	Bacterial Cytochrome P450	Infection
Mtb-IN-12 (Compound 5m) is a dual-target inhibitor that can target the CYP125 (K_D: 40 nM; K_I: 0.1 μM) and CYP142 (K_D: 160 nM; K_I: 0.05 μM) enzymes of Mycobacterium tuberculosis. Mtb-IN-12 exhibits good inhibitory activity against both drug-sensitive strains and multidrug-resistant tuberculosis strains, with low toxicity to macrophages. Mtb-IN-12 can be used in the research of anti-tuberculosis drugs .

HY-149333

BO-1	Bacterial	Infection
BO-1 is a benzoate ester with antibacterial activity. BO-1 inhibits multidrug-resistant Staphylococcus aureus, and acts function synergistically with antibiotic, such as Ciprofloxacin (HY-B0356). BO-1 can reverse the resistance of antibiotic-resistant S. aureus strains, and decreases the level of inflammatory factors IL-6 and C-reactive protein in vivo in mice .

HY-119387

Chevalone B	Bacterial	Infection
Chevalone B was isolated from the ethyl acetate extract of the marine sponge-associated fungus Aspergillus similanensis. The structure of Chevalone B was confirmed by 1D and 2D NMR spectroscopy. Chevalone B showed antimicrobial activity against Gram-positive and Gram-negative bacteria, Candida albicans, and multidrug-resistant strains from the environment. Studies on Chevalone B have shown its potential value in antimicrobial applications.

HY-178147

Antimalarial agent 52	Parasite	Infection
Antimalarial agent 52 is an orally active formation of synthetic hemozoin (β-hematin) inhibitor with an IC₅₀ of 6.6 μM. Antimalarial agent 52 exhibits in vitro antiplasmodial activity against P. falciparum Pf3D7, PfDd2 strains and P. knowlesi with IC₅₀s of 6.1, 6.4 and 3.3 nM. Antimalarial agent 52 remain highly effective against multidrug-resistant strains and demonstrates curative activity in the P. berghei mouse model .

HY-130004

MsbA-IN-6	Antibiotic Bacterial	Infection
MsbA-IN-6 is a potent inhibitor of MsbA. MsbA-IN-6 is an antibiotic. Gram-negative ATP-binding cassette (ABC) transporter MsbA, an essential inner membrane protein, transports lipopolysaccharide from the inner leaflet to the periplasmic face of the inner membrane. MsbA-IN-6 kills Escherichia coli through inhibition of its ATPase and transport activity, with no loss of activity against clinical multidrug-resistant strains .

HY-P5484

SMAP-18	Bacterial	Others
SMAP-18 is a biological active peptide. (SMAP-18 is a 18-amino acid residue peptide amide which is a truncated form of SMAP-29. Sheep myeloid antimicrobial peptide-29 (SMAP-29) displays extremely high antimicrobial activity against Pseudomonas strains, other Gram-negative bacteria, and multidrug-resistant pathogens. SMAP-18 displays much higher cell selectivity as compared to parental SMAP-29 because of its decreased hemolytic activity and retained antimicrobial activity.)

HY-151599

Pks13-TE inhibitor 3	Bacterial	Infection
Pks13-TE inhibitor 3 (compound 23) is a 13-Thioesterase (Pks13-TE) inhibitor (IC₅₀=1.55 μM). Pks13-TE inhibitor 3 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0625-0.25 μg/mL). Pks13-TE inhibitor 3 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .

HY-151598

Pks13-TE inhibitor 2	Bacterial	Infection
Pks13-TE inhibitor 2 (compound 32) is a 13-Thioesterase (Pks13-TE) inhibitor (IC₅₀=1.30 μM). Pks13-TE inhibitor 2 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0039-0.0078 μg/mL). Pks13-TE inhibitor 2 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .

HY-15980

GNF179 (Metabolite)	Parasite	Infection
GNF179 metabolite is the metabolite of GNF179, which is an optimized 8,8-dimethyl IP analog that exhibited the potency(4.8 nM against the multidrug resistant strain W2) in vitro metabolic stability and in vivo oral bioavailability.

HY-170970

Mtb-IN-10	Bacterial	Infection
Mtb-IN-10 (Compound P15) is a Rv1625c/Cya activator that regulates cAMP metabolism to influence the growth of Mycobacterium tuberculosis (Mtb). Mtb-IN-10 exhibits an EC₅₀ of 1.96 µM in an Mtb-infected macrophage model and demonstrates 58.0% oral bioavailability in mice at a 20 mg/kg dose. It may regulate intracellular signaling and disrupt cholesterol metabolism in Mtb, thereby inhibiting bacterial proliferation. Mtb-IN-10 holds potential for tuberculosis (TB) research, particularly for combating multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) Mtb strains .

HY-P3328

MDP1	Bacterial	Infection
MDP1, a Melittin-derived peptide, alters the integrity of both Gram-positive and Gram-negative bacterial membranes and kills the bacteria via membrane damages. MDP1 has a high-antibacterial activity against multidrug resistant (MDR) and reference strains of S. aureus, E. coli, and P. aeruginosa .

HY-174323

Anti-MRSA agent 28	Bacterial DNA/RNA Synthesis	Infection
Anti-MRSA agent 28 is an antibacterial agent against multidrug resistant (MDR) gram-positive strains with MICs of 0.06-0.125 μg/mL. Anti-MRSA agent 28 can target DNA polymerase IIIC to reduce the amount of genomic DNA with the IC₅₀ of 3.80 μg/mL. Anti-MRSA agent 28 has good antibacterial activity and reduces inflammation. Anti-MRSA agent 28 can be used against gram-positive strains and infectious conditions.

HY-137985

Mer-NF5003F Stachybotrydial; F 1839M; Stachybotrydial	HSV Virus Protease	Infection
Mer-NF5003F (Stachybotrydial; F 1839M), a sesquiterpene isolated from Stachybotrys, inhibits avian medulloblastoma virus (AMV) protease (IC₅₀=7.8 μM). Mer-NF5003F inhibits sialyltransferase 6N (ST6N), ST3O, and ST3N (IC₅₀=0.61, 6.7, and 10 μg/mL, respectively), and fucosyltransferase (IC₅₀=11.3 μg/mL). Mer-NF5003F has in vitro activity against herpes simplex virus HSV-1 (IC₅₀=4.32 μg/mL) and multidrug-resistant Plasmodium falciparum K1 strain (IC₅₀=0.85 μg/mL).

HY-118962

E913	CCR HIV	Infection
E913 is a CCR5 antagonist that competes with the binding of antibodies to CCR5 which recognize the C-terminal half of the second extracellular loop (ECL2B) of CCR5. E913 can specifically block the binding of macrophage inflammatory protein-1alpha (MIP-1alpha) to CCR5 (IC₅₀ = 0.002 μM) and MIP-1alpha-elicited cellular Ca ²⁺ mobilization (IC₅₀ = 0.02 μM). E913 inhibits the replication of laboratory and primary R5 HIV-1 strains as well as various multidrug-resistant monocyte/macrophage tropic (R5) HIV-1 (IC₅₀ = 0.03-0.06 μM). E913 can be used for the research of infection, such as HIV-1 infection .

HY-124195

Antitubercular agent-57	Bacterial	Infection
Antitubercular agent-57 is a selective antimycobacterial agent with low in vitro toxicity against mammalian cell lines including hepatocyte cell lines. Antitubercular agent-57 exhibits activity against drug-sensitive, multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains, and shows no cross-resistance with first-line or second-line antitubercular agents. Antitubercular agent-57 has no activity against Gram-positive bacteria, Gram-negative bacteria and fungal strains. Antitubercular agent-57 can be used in the research of tuberculosis and multidrug-resistant tuberculosis .

HY-N18102

3,4-Seco-mansumbinoic acid	Bacterial	Infection
3,4-Seco-mansumbinoic acid (Compound 2) is an Antibacterial agent. 3,4-Seco-mansumbinoic acid can be isolated from the oleo-resin of Commiphora molmol. 3,4-Seco-mansumbinoic acid exhibits in vitro anti-staphylococcal activity, with the strongest activity against the multidrug-resistant Staphylococcus aureus strain SA-1199B (MIC 4 μg/mL) 3,4-Seco-mansumbinoic acid displays weak potentiation of Ciprofloxacin (HY-B0356) and Tetracycline (HY-A0107) activity against strains of Salmonella enterica serovar Typhimurium SL1344 and L10. 3,4-Seco-mansumbinoic acid can be used for the research of multidrug-resistant bacterial infection (Staphylococcus aureus, Salmonella enterica serovar Typhimurium) .

HY-W277771

4-(3-Phenylpropoxy)aniline	Parasite	Infection
4-(3-Phenylpropoxy)aniline (Compound 3g) is an antimalarial agent targeting Plasmodium. 4-(3-Phenylpropoxy)aniline is promising for research of multidrug-resistant Plasmodium strains .

HY-182347

LSPN954	Parasite	Infection
LSPN954 (compound 4i) is an indole-based peptidomimetic antiplasmodial agent that exhibits submicromolar activity against both sensitive and multidrug-resistant Plasmodium falciparum strains, with low cytotoxicity to human cells and a high selectivity index. LSPN954 shows slow-acting inhibitory activity, allowing the initial development of Plasmodium followed by morphological changes, and its activity is independent of the inhibition of plastid-dependent isoprenoid biosynthesis. LSPN954 can be used in malaria research .

HY-181419

Antimycobacterial agent-16	Bacterial	Infection
Antimycobacterial agent-16 is a pyrazinamide derivative and antimycobacterial agent with a selectivity index >25 against HepG2 cells.Antimycobacterial agent-16 does not undergo hydrolysis by mycobacterial pyrazinamidase.Antimycobacterial agent-16 exerts activity against Mycobacterium tuberculosis H37Rv, multidrug-resistant Mycobacterium tuberculosis strains, and Mycobacterium kansasii.Antimycobacterial agent-16 shows no inhibitory activity against mycobacterial enoyl-ACP reductase (InhA).Antimycobacterial agent-16 has low cytotoxicity against HepG2 cells.Antimycobacterial agent-16 can be used for the research of tuberculosis .

HY-181888

GRL-142	HIV HIV Protease	Infection
GRL-142 is a potent HIV-1 protease inhibitor capable of crossing the blood-brain barrier. GRL-142 exhibits extremely high inhibitory activity against both wild-type and multidrug-resistant strains (IC₅₀=0.0094 nM). GRL-142 acts synergistically with the P2/P2' segments via a unique scaffold binding mechanism, utilizes fluorine-mediated stable interactions to maintain its bioactive conformation, adapts to p51 HIV-1 protease mutants, and maintains the flap-closed state by directly acting on the flap tip residues. GRL-142 disrupts the flap-water hydrogen bond network of wild-type protease, thereby effectively blocking viral replication. GRL-142 can be used to study HIV-1 infection and the associated neurocognitive disorder (HAND) .

HY-180854

Antitubercular agent-55	Bacterial	Infection
Antitubercular agent-55 (Compound 2e) is an anti-tuberculous agent. Antitubercular agent-55 exhibits significant inhibitory activity against the standard strain of Mycobacterium tuberculosis H37Rv and also has moderate inhibitory activity against multidrug-resistant TB (MDR-TB). Antitubercular agent-55 has a strong affinity for the key enzyme InhA involved in the biosynthesis of mycotic acids. Antitubercular agent-55 can be used for research on tuberculosis infection caused by Mycobacterium tuberculosis.

HY-180324

Candidone	Bcl-2 Family Caspase p38 MAPK MMP Apoptosis Bacterial DNA/RNA Synthesis Survivin	Infection Cancer
Candidone is a type of flavanone phenolic compound with anti-cancer and antibacterial activities. Candidone inhibits the proliferation of hepatoblastoma and cholangiocarcinoma cells and induces their apoptosis by up-regulating p21, Bax, and caspase 3/9, and down-regulating Bcl-2 and survivin. It reduces the metastatic ability of cancer cells by inhibiting the expression of phosphorylated p38 and matrix metalloproteinase MMP-9. Candidone has inhibitory effects on multidrug-resistant bacterial strains. Candidone binds to the base pairs of DNA in a groove-binding manner, thereby slightly altering the conformation of DNA .

HY-P11592

KIKIKPWWWPKIKIK-NH2	Bacterial	Infection
KIKIKPWWWPKIKIK-NH2 is a β-turn antimicrobial peptide. KIKIKPWWWPKIKIK-NH2 can inhibit bacterial biofilm formation and bind to lipopolysaccharid. KIKIKPWWWPKIKIK-NH2 shows wound-healing ability in mice bacteria-infected full-thickness wound models. KIKIKPWWWPKIKIK-NH2 can be used for the research of bacterial infection .

HY-181100

DHFR-IN-26	Dihydrofolate reductase (DHFR) Bacterial	Infection
DHFR-IN-26 is an Escherichia coli dihydrofolate reductase (ecDHFR) inhibitor with an IC₅₀ of 0.75 nM. DHFR-IN-26 exerts broad-spectrum antibacterial activity. DHFR-IN-26 disrupts folate metabolism, nucleotide synthesis, and bacterial amino acid metabolic pathways. DHFR-IN-26 disrupts bacterial inner membranes, inhibited biofilm formation, and attenuated phage-related processes. DHFR-IN-26 shows lower toxicity to non-cancerous cells. DHFR-IN-26 can be used for the research of bacterial infections (including infections caused by methicillin-resistant Staphylococcus aureus, multidrug-resistant Escherichia coli, multidrug-resistant Pseudomonas aeruginosa, and lysogenic bacteria) .

HY-183782

SA1103064	Antibiotic Bacterial	Infection
SA1103064 is a potent antibiotic with antibacterial activity against multiple resistant bacterial strains. SA1103064 binds to the bacterial ribosome's nascent peptide exit tunnel. SA1103064 can be used for the research of bacterial infections .

HY-181010

HDAC1-IN-12	HDAC Parasite	Infection
HDAC1-IN-12 is a Plasmodium falciparum HDAC1 (PfHDAC1) inhibitor with an IC₅₀ of 4.1 nM against Pf3D7. HDAC1-IN-12 inhibits PfHDAC1, upregulates histone H₃ acetylation in P. falciparum parasites, downregulates malaria invasion-related gene expression, and exhibits favorable safety profiles, improved physicochemical properties, and potent in vivo antimalarial activity. HDAC1-IN-12 can be used for the research of malaria .

Cat. No.	Product Name	Target	Research Area